The most common adverse reactions reported in clinical trials were injection site reactions (erythema, pruritus, pain) occurring in approximately 8-13% of patients
However, in vivo studies primarily in humans are needed to confirm these promising preclinical findings
Consult a Professional Before you initiate CJC-1295/Ipamorelin or any peptide therapy, its very important to consult a qualified health care provider
Many performance-related peptides are banned in competitive sports, including growth hormone-releasing peptides and related mimetics regulated by anti-doping organizations
Within about three days, my skin felt fresher and had a new liveliness to it
Safety and Research-Use Considerations KLOW is sold for laboratory research use only and is not intended for human consumption, diagnosis, or treatment